Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $619.1 million.

  • Corcept Therapeutics' Retained Earnings rose 2068.47% to $619.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $619.1 million, marking a year-over-year increase of 2068.47%. This contributed to the annual value of $543.7 million for FY2024, which is 3508.07% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Retained Earnings of $619.1 million as of Q3 2025, which was up 2068.47% from $599.4 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Retained Earnings registered a high of $619.1 million during Q3 2025, and its lowest value of $105.9 million during Q1 2021.
  • Moreover, its 5-year median value for Retained Earnings was $339.8 million (2023), whereas its average is $357.7 million.
  • In the last 5 years, Corcept Therapeutics' Retained Earnings surged by 152705.07% in 2021 and then soared by 2068.47% in 2025.
  • Corcept Therapeutics' Retained Earnings (Quarter) stood at $195.0 million in 2021, then soared by 52.02% to $296.4 million in 2022, then soared by 35.81% to $402.5 million in 2023, then surged by 35.08% to $543.7 million in 2024, then increased by 13.86% to $619.1 million in 2025.
  • Its last three reported values are $619.1 million in Q3 2025, $599.4 million for Q2 2025, and $564.3 million during Q1 2025.